Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors

2023-507564-39-00 Protocol AMBER Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 11 Mar 2019 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 21 sites · Protocol AMBER

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 2,442
Countries 1
Sites 21

Patients with Advanced Solid Tumors

Key facts

Sponsor
Tesaro Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
11 Mar 2019 → ongoing
Decision date (initial)
2024-01-30
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-507564-39-00
EudraCT number
2018-002143-29
ClinicalTrials.gov
NCT02817633

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with Advanced Solid Tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Tesaro Inc.

Sponsor organisation
Tesaro Inc.
Address
1000 Winter Street Suite 3300
City
Waltham
Postcode
02451-1230
Country
United States

Scientific contact point

Organisation
Tesaro Inc.
Contact name
EU GSK Clinical Trials Call Center

Public contact point

Organisation
Tesaro Inc.
Contact name
Clinical Trial Mailbox

Locations

1 EU/EEA country · 21 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruitment ended 1,221 21
Rest of world
United States, Korea, Republic of
1,221

Investigational sites

Spain

21 sites · Ongoing, recruitment ended
Hospital Universitario Virgen De La Victoria
Oncology, Calle Del Arroyo Teatinos Sn, 29010, Malaga
Hospital De Jerez De La Frontera
Oncology, Carretera De La Ronda Circunvalacion S/n, 11408, Jerez De La Frontera
Complejo Hospitalario Universitario Insular Materno Infantil
Oncology, Autovia Del Sur S/n, 35017, Las Palmas De Gran Canaria
Hospital Clinico Universitario Lozano Blesa
Digestive, Avenida De San Juan Bosco 15, 50009, Zaragoza
Hospital Universitari De Girona Doctor Josep Trueta
Oncology, Avinguda De Franca S/n, 17007, Girona
Hospital Universitario La Paz
Oncology, Paseo Castellana 261, 28046, Madrid
Hospital Universitario Marques De Valdecilla
Oncology, Avenida Valdecilla Sn, 39008, Santander
Hospital Universitario Y Politecnico La Fe
Oncology, Avenida De Fernando Abril Martorell 106, 46026, Valencia
Institut Catala D'oncologia
Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
University Hospital Virgen Del Rocio S.L.
Oncology, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitari Dexeus Grupo Quironsalud
Oncology, Calle De Sabino Arana 5-19, 08028, Barcelona
Hospital Universitari Vall D Hebron
Oncology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Clinica Universidad De Navarra
Oncology, Avenue Pio XII 36, 31008, Pamplona
Hospital De La Santa Creu I Sant Pau
Oncology, Calle De San Antonio Maria Claret 167, 08025, Barcelona
Hospital Universitario De Jaen
Oncology, Avenida Del Ejercito Espanol 10, 23007, Jaen
Micancer Center S.L.P.
Oncology, Calle Del Doctor Roux 76 Planta 5, 08017, Barcelona
Hospital Universitario Puerta De Hierro De Majadahonda
Hematology, Calle De Manuel De Falla 1, 28222, Majadahonda
Hospital Clinic De Barcelona
Oncology, Calle Villarroel 170, 08036, Barcelona
University Hospital Son Espases
Oncology, Carretera Valldemossa 79, 07120, Palma

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2019-03-11 2019-03-15 2025-09-05

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-18 Spain Acceptable
2024-01-30
2024-01-30
2 SUBSTANTIAL MODIFICATION SM-1 2024-05-27 Spain Acceptable
2024-07-19
2024-07-31
3 SUBSTANTIAL MODIFICATION SM-2 2024-10-25 Spain Acceptable
2025-01-15
2025-01-15
4 SUBSTANTIAL MODIFICATION SM-3 2025-02-14 Spain Acceptable
2025-03-27
2025-04-23
5 SUBSTANTIAL MODIFICATION SM-4 2025-10-27 Spain Acceptable
2025-11-28
2025-12-19